{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:37:24Z","timestamp":1793317044834,"version":"4.5.0"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Cognitive impairments are a common feature of synucleinopathies such as Parkinson\u2019s Disease Dementia and Dementia with Lewy Bodies. These pathologies are characterized by accumulation of Lewy bodies and Lewy neurites as well as neuronal cell death. Alpha-synuclein is the main proteinaceous component of Lewy bodies and Lewy neurites. To model these pathologies <jats:italic>in vivo<\/jats:italic>, toxins that selectively target certain neuronal populations or different means of inducing alpha-synuclein aggregation can be used. Alpha-synuclein accumulation can be induced by genetic manipulation, viral vector overexpression or the use of preformed fibrils of alpha-synuclein. In this review, we summarize the cognitive impairments associated with different models of synucleinopathies and relevance to observations in human diseases.<\/jats:p>","DOI":"10.3389\/fnagi.2024.1369733","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:57:12Z","timestamp":1721624232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cognitive dysfunction in animal models of human lewy-body dementia"],"prefix":"10.3389","volume":"16","author":[{"given":"Caroline","family":"Haikal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham M.","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Kaplitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease.","volume":"289","author":"Aarsland","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study.","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00401-019-02010-2","article-title":"Selective vulnerability in \u03b1-synucleinopathies.","volume":"138","author":"Alegre-Abarrategui","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.","volume":"281","author":"Anderson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00697388","article-title":"Loss of neurons in the nucleus basalis of Meynert in Alzheimer\u2019s disease, paralysis agitans and Korsakoff\u2019s Disease.","volume":"61","author":"Arendt","year":"1983","journal-title":"Acta Neuropathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1600-0404.1995.tb00443.x","article-title":"Hypersensitivity of cortical muscarinic receptors in Parkinson\u2019s disease demonstrated by PET.","volume":"91","author":"Asahina","year":"1995","journal-title":"Acta Neurol. Scand."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1212\/01.wnl.0000036908.39696.fd","article-title":"Fluctuations in attention: PD dementia vs DLB with parkinsonism.","volume":"59","author":"Ballard","year":"2002","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","article-title":"Differences in neuropathologic characteristics across the Lewy body dementia spectrum.","volume":"67","author":"Ballard","year":"2006","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2019.10.010","article-title":"Amyloid-Beta (A\u03b2) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with A\u03b2 Pathology.","volume":"105","author":"Bassil","year":"2020","journal-title":"Neuron"},{"key":"B10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00002826-200203000-00009","article-title":"Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson\u2019s disease.","volume":"25","author":"Bergman","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1176\/appi.ajgp.12.5.542","article-title":"Donepezil in the treatment of dementia with Lewy bodies.","volume":"12","author":"Beversdorf","year":"2004","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1212\/01.wnl.0000269666.62598.1c","article-title":"Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies.","volume":"69","author":"Beyer","year":"2007","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/1098-2396(20001201)38:3<363::AID-SYN16>3.0.CO;2-A","article-title":"Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice.","volume":"38","author":"Bezard","year":"2000","journal-title":"Synapse"},{"key":"B14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","article-title":"The cholinergic system and Parkinson disease.","volume":"221","author":"Bohnen","year":"2011","journal-title":"Behav. Brain Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","article-title":"Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study.","volume":"60","author":"Bohnen","year":"2003","journal-title":"Arch. Neurol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3575","article-title":"Structural and functional characterization of two alpha-synuclein strains.","volume":"4","author":"Bousset","year":"2013","journal-title":"Nat. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JPD-212566","article-title":"Effects of alpha-synuclein targeted antisense oligonucleotides on Lewy body-like pathology and behavioral disturbances induced by injections of pre-formed fibrils in the mouse motor cortex.","volume":"11","author":"Boutros","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease.","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1136\/jnnp.52.11.1228","article-title":"Visuospatial working memory in Parkinson\u2019s disease.","volume":"52","author":"Bradley","year":"1989","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0022-510x(83)90045-x","article-title":"Pathological changes in the nucleus of Meynert in Alzheimer\u2019s and Parkinson\u2019s diseases.","volume":"59","author":"Candy","year":"1983","journal-title":"J. Neurol. Sci."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12091200","article-title":"LRRK2 deficiency aggravates sleep deprivation-induced cognitive loss by perturbing synaptic pruning in mice.","volume":"12","author":"Cheng","year":"2022","journal-title":"Brain Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","article-title":"A progressive mouse model of Parkinson\u2019s disease: The Thy1-aSyn (\u201cLine 61\u201d) mice.","volume":"9","author":"Chesselet","year":"2012","journal-title":"Neurotherapeutics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/mds.25842","article-title":"The source of the memory impairment in Parkinson\u2019s disease: Acquisition versus retrieval.","volume":"29","author":"Chiaravalloti","year":"2014","journal-title":"Mov Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14802\/jmd.19046","article-title":"Modeling \u03b1-synuclein propagation with preformed fibril injections.","volume":"12","author":"Chung","year":"2019","journal-title":"J. Mov. Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","article-title":"Lewy- and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: Which is more important?","volume":"134","author":"Compta","year":"2011","journal-title":"Brain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","article-title":"Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein.","volume":"149","author":"Cremades","year":"2012","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jnc.15461","article-title":"Brain iron enrichment attenuates \u03b1-synuclein spreading after injection of preformed fibrils.","volume":"159","author":"Dauer N\u00e9e Joppe","year":"2021","journal-title":"J. Neurochem."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay3069","article-title":"APOE genotype regulates pathology and disease progression in synucleinopathy.","volume":"12","author":"Davis","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"26181","DOI":"10.1073\/pnas.1902280116","article-title":"Translational implications of the anatomical nonequivalence of functionally equivalent cholinergic circuit motifs.","volume":"116","author":"Disney","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson\u2019s disease dementia: A randomized, double-blind efficacy and safety study.","volume":"27","author":"Dubois","year":"2012","journal-title":"Mov. Disord."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00574-1","article-title":"Hippocampal subfield vulnerability to \u03b1-synuclein pathology precedes neurodegeneration and cognitive dysfunction.","volume":"9","author":"Dues","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00415-006-0175-2","article-title":"Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson\u2019s disease.","volume":"253","author":"Dujardin","year":"2006","journal-title":"J. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease.","volume":"22","author":"Emre","year":"2007","journal-title":"Mov. Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/mds.27810","article-title":"Seeding of protein aggregation causes cognitive impairment in rat model of cortical synucleinopathy.","volume":"34","author":"Espa","year":"2019","journal-title":"Mov. Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s100720200022","article-title":"Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease.","volume":"23","author":"Fabbrini","year":"2002","journal-title":"Neurol. Sci."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.745438","article-title":"Experimental models of cognitive impairment for use in Parkinson\u2019s disease research: The distance between reality and ideal.","volume":"13","author":"Fan","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jalz.2017.09.014","article-title":"The limbic and neocortical contribution of \u03b1-synuclein, tau, and amyloid \u03b2 to disease duration in dementia with Lewy bodies.","volume":"14","author":"Ferman","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.neurobiolaging.2006.06.013","article-title":"Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.","volume":"28","author":"Freichel","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gaitpost.2016.08.009","article-title":"Motor performance differentiates individuals with Lewy body dementia, Parkinson\u2019s and Alzheimer\u2019s disease.","volume":"50","author":"Fritz","year":"2016","journal-title":"Gait Post."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1212\/01.wnl.0000242630.52203.8f","article-title":"Clinical phenotype of Parkinson disease dementia.","volume":"67","author":"Galvin","year":"2006","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/s0896-6273(02)00682-7","article-title":"Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.","volume":"34","author":"Giasson","year":"2002","journal-title":"Neuron"},{"key":"B42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1034\/j.1600-0404.2003.00211.x","article-title":"Rivastigmine (Exelon) for dementia in patients with Parkinson\u2019s disease.","volume":"108","author":"Giladi","year":"2003","journal-title":"Acta Neurol. Scand."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005777","article-title":"Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration.","volume":"4","author":"Gispert","year":"2009","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/ana.22117","article-title":"Dysexecutive syndrome: Diagnostic criteria and validation study.","volume":"68","author":"Godefroy","year":"2010","journal-title":"Ann Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1212\/CON.0000000000000309","article-title":"Lewy body dementias: Dementia with Lewy bodies and parkinson disease dementia.","volume":"22","author":"Gomperts","year":"2016","journal-title":"Continuum"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/brain\/awu193","article-title":"Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson\u2019s disease.","volume":"137","author":"Hall","year":"2014","journal-title":"Brain"},{"key":"B47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.nbd.2013.04.017","article-title":"A novel \u03b1-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of \u03b1-synuclein-GFP.","volume":"56","author":"Hansen","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.brainresbull.2018.10.003","article-title":"Cerebral inoculation of human A53T \u03b1-synuclein reduces spatial memory decline and amyloid-\u03b2 aggregation in APP\/PS1 transgenic mice of Alzheimer\u2019s disease.","volume":"143","author":"Hao","year":"2018","journal-title":"Brain Res. Bull."},{"key":"B49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s004010100390","article-title":"Cortical Lewy body pathology in the diagnosis of dementia.","volume":"102","author":"Harding","year":"2001","journal-title":"Acta Neuropathol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/cercor\/bhab244","article-title":"\u03b1-Synuclein selectively impairs motor sequence learning and value sensitivity: Reversal by the adenosine a2a receptor antagonists.","volume":"32","author":"He","year":"2022","journal-title":"Cereb. Cortex"},{"key":"B51","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: The inevitability of dementia at 20 years.","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134316","article-title":"\u03b1-Synuclein pathology in Parkinson\u2019s disease and related \u03b1-synucleinopathies.","volume":"709","author":"Henderson","year":"2019","journal-title":"Neurosci. Lett."},{"key":"B53","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jnen\/nlw070","article-title":"Distribution and load of amyloid-\u03b2 pathology in Parkinson disease and dementia with Lewy bodies.","volume":"75","author":"Hepp","year":"2016","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/13803390490515469","article-title":"Recognition memory in Parkinson\u2019s disease with and without dementia: Evidence inconsistent with the retrieval deficit hypothesis.","volume":"27","author":"Higginson","year":"2005","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/01.wnl.0000191154.78131.f6","article-title":"Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways.","volume":"65","author":"Hilker","year":"2005","journal-title":"Neurology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1212\/wnl.37.3.485","article-title":"Spatial disorientation as an early symptom of Parkinson\u2019s disease.","volume":"37","author":"Hovestadt","year":"1987","journal-title":"Neurology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.expneurol.2016.05.040","article-title":"Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy.","volume":"283","author":"Hu","year":"2016","journal-title":"Exp. Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2147\/NDT.S235562","article-title":"Phosphorylation of Tau and \u03b1-Synuclein Induced neurodegeneration in MPTP mouse model of Parkinson\u2019s disease.","volume":"16","author":"Hu","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B59","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s12035-022-03119-4","article-title":"Endothelial LRP1-ICD accelerates cognition-associated alpha-synuclein pathology and neurodegeneration through PARP1 activation in a mouse model of Parkinson\u2019s disease.","volume":"60","author":"Huang","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.14336\/AD.2021.0517","article-title":"Adeno-associated virus expression of \u03b1-synuclein as a tool to model Parkinson\u2019s disease: Current understanding and knowledge gaps.","volume":"12","author":"Huntington","year":"2021","journal-title":"Aging Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/wnl.54.10.1916","article-title":"Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson\u2019s disease.","volume":"54","author":"Hurtig","year":"2000","journal-title":"Neurology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.114145","article-title":"Cognitive deficits and altered cholinergic innervation in young adult male mice carrying a Parkinson\u2019s disease Lrrk2G2019S knockin mutation.","volume":"355","author":"Hussein","year":"2022","journal-title":"Exp. Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: Convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies.","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia.","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann. Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"E4016","DOI":"10.1073\/pnas.1309143110","article-title":"Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model.","volume":"110","author":"Janezic","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00401-008-0347-5","article-title":"Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.","volume":"115","author":"Jellinger","year":"2008","journal-title":"Acta Neuropathol."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1016-8","article-title":"Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease?","volume":"16","author":"Jellinger","year":"2018","journal-title":"BMC Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/NEN.0b013e31816362aa","article-title":"Striatal beta-amyloid deposition in Parkinson disease with dementia.","volume":"67","author":"Kalaitzakis","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neulet.2009.05.083","article-title":"Clinical correlates of pathology in the claustrum in Parkinson\u2019s disease and dementia with Lewy bodies.","volume":"461","author":"Kalaitzakis","year":"2009","journal-title":"Neurosci. Lett."},{"key":"B70","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2007.06.008","article-title":"Screening for cognitive deficits in Parkinson\u2019s disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument.","volume":"14","author":"Kalbe","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"B71","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1176\/appi.neuropsych.19070165","article-title":"Topography of cholinergic changes in dementia with Lewy bodies and key neural network hubs.","volume":"32","author":"Kanel","year":"2020","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"ENEURO.0009","DOI":"10.1523\/ENEURO.0009-20.2020","article-title":"Chronic \u03b1-Synuclein Accumulation in Rat Hippocampus Induces Lewy Bodies Formation and Specific Cognitive Impairments.","volume":"7","author":"Kasongo","year":"2020","journal-title":"eNeuro"},{"key":"B73","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.parkreldis.2004.10.010","article-title":"Visuo-spatial processing in Parkinson\u2019s disease: Evidence for diminished visuo-spatial sketch pad and central executive resources.","volume":"11","author":"Kemps","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"key":"B74","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease.","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s12276-022-00895-w","article-title":"Inflammation promotes synucleinopathy propagation.","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"11441","DOI":"10.1073\/pnas.0702717104","article-title":"Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice.","volume":"104","author":"Kitada","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of Synucleinopathies.","volume":"16","author":"Koga","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"B78","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/bpa.12536","article-title":"Protein astrogliopathies in human neurodegenerative diseases and aging.","volume":"27","author":"Kovacs","year":"2017","journal-title":"Brain Pathol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00401-003-0705-2","article-title":"Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson\u2019s disease.","volume":"106","author":"K\u00f6vari","year":"2003","journal-title":"Acta Neuropathol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3233\/JAD-161109","article-title":"Long-term cognitive decline in dementia with Lewy bodies in a large multicenter, international cohort.","volume":"57","author":"Kramberger","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B81","article-title":"Zue pathologischen anatomie der paralysis agitans.","volume":"50","author":"Lewy","year":"1913","journal-title":"Detsch Z. Nervenhaeilkunde"},{"key":"B82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/jnnp.54.1.25","article-title":"Differential memory and executive functions in demented patients with Parkinson\u2019s and Alzheimer\u2019s disease.","volume":"54","author":"Litvan","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B83","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01288-2","article-title":"Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro.","volume":"9","author":"Marotta","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awt037","article-title":"Prion-like spreading of pathological \u03b1-synuclein in brain.","volume":"136","author":"Masuda-Suzukake","year":"2013","journal-title":"Brain"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010400","article-title":"Crucial role of FABP3 in \u03b1Syn-induced reduction of septal GABAergic neurons and cognitive decline in mice.","volume":"22","author":"Matsuo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s004019900168","article-title":"Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson\u2019s disease.","volume":"100","author":"Mattila","year":"2000","journal-title":"Acta Neuropathol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s004010050843","article-title":"Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson\u2019s disease.","volume":"95","author":"Mattila","year":"1998","journal-title":"Acta Neuropathol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0733-8619(05)70230-9","article-title":"SPECTRUM OF PARKINSON\u2019S DISEASE, PARKINSON\u2019S DEMENTIA, AND LEWY BODY DEMENTIA.","volume":"18","author":"McKeith","year":"2000","journal-title":"Neurol. Clin."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study.","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium.","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.23557","article-title":"Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial.","volume":"72","author":"Mori","year":"2012","journal-title":"Ann. Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1212\/01.wnl.0000145764.70698.4e","article-title":"Visual perception in Parkinson disease dementia and dementia with Lewy bodies.","volume":"63","author":"Mosimann","year":"2004","journal-title":"Neurology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S1474-4422(17)30074-1","article-title":"The prognosis of dementia with Lewy bodies.","volume":"16","author":"Mueller","year":"2017","journal-title":"Lancet Neurol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/ana.410150503","article-title":"Parkinson\u2019s disease: Neuron loss in the nucleus basalis without concomitant Alzheimer\u2019s disease.","volume":"15","author":"Nakano","year":"1984","journal-title":"Ann Neurol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mds.10633","article-title":"Comparison of dementia with Lewy bodies to Alzheimer\u2019s disease and Parkinson\u2019s disease with dementia.","volume":"19","author":"Noe","year":"2004","journal-title":"Mov. Disord."},{"key":"B97","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.expneurol.2017.10.017","article-title":"Critical appraisal of pathology transmission in the \u03b1-synuclein fibril model of Lewy body disorders.","volume":"299","author":"Nouraei","year":"2018","journal-title":"Exp. Neurol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/mds.22877","article-title":"PDD-Short Screen: A brief cognitive test for screening dementia in Parkinson\u2019s disease.","volume":"25","author":"Pagonabarraga","year":"2010","journal-title":"Mov. Disord."},{"key":"B99","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1093\/brain\/awac171","article-title":"Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson\u2019s disease.","volume":"145","author":"Pan","year":"2022","journal-title":"Brain"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12829","article-title":"Investigating key factors underlying neurodegeneration linked to alpha-synuclein spread.","volume":"48","author":"Pang","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/089198879500800308","article-title":"Differentiation of the dementias of Alzheimer\u2019s and Parkinson\u2019s disease with the dementia rating scale.","volume":"8","author":"Paolo","year":"1995","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3988\/jcn.2011.7.1.19","article-title":"Dementia with Lewy bodies versus Alzheimer\u2019s disease and Parkinson\u2019s disease dementia: A comparison of cognitive profiles.","volume":"7","author":"Park","year":"2011","journal-title":"J. Clin. Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/mdc3.13319","article-title":"The cholinergic brain in Parkinson\u2019s disease.","volume":"8","author":"Pasquini","year":"2021","journal-title":"Mov. Disord. Clin. Pract."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070274","article-title":"Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson\u2019s disease.","volume":"8","author":"Paumier","year":"2013","journal-title":"PLoS One"},{"key":"B105","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/00001756-199403000-00002","article-title":"Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer\u2019s disease.","volume":"5","author":"Perry","year":"1994","journal-title":"Neuroreport"},{"key":"B106","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JPD-171248","article-title":"Best practices for generating and using alpha-synuclein pre-formed fibrils to model Parkinson\u2019s disease in rodents.","volume":"8","author":"Polinski","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/mds.1204","article-title":"Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial.","volume":"16","author":"Reading","year":"2001","journal-title":"Mov. Disord."},{"key":"B108","author":"Rodriguiz","year":"2006","journal-title":"Assessments of Cognitive Deficits in Mutant Mice. In: Levin, ED, Buccafusco JJ, (eds) Animal Models of Cognitive Impairment"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010357","article-title":"Cognitive decline in dementia with Lewy bodies: A 5-year prospective cohort study.","volume":"6","author":"Rongve","year":"2016","journal-title":"BMJ Open"},{"key":"B110","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/nan.12294","article-title":"Cortical Lewy bodies and A\u03b2 burden are associated with prevalence and timing of dementia in Lewy body diseases.","volume":"42","author":"Ruffmann","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WAD.0b013e31819c5ef4","article-title":"Parkinson disease with dementia: Comparing patients with and without Alzheimer pathology.","volume":"23","author":"Sabbagh","year":"2009","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B112","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1212\/WNL.0b013e3181ab2b58","article-title":"Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET.","volume":"73","author":"Shimada","year":"2009","journal-title":"Neurology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00401-019-02032-w","article-title":"Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy.","volume":"138","author":"Singh","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41380-018-0075-8","article-title":"Acute transient cognitive dysfunction and acute brain injury induced by systemic inflammation occur by dissociable IL-1-dependent mechanisms.","volume":"24","author":"Skelly","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104708","article-title":"Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded \u03b1-synuclein inclusions.","volume":"134","author":"Stoyka","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"ENEURO.458","DOI":"10.1523\/ENEURO.0458-20.2021","article-title":"Templated \u03b1-synuclein inclusion formation is independent of endogenous tau.","volume":"8","author":"Stoyka","year":"2021","journal-title":"eNeuro"},{"key":"B117","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.nbd.2018.05.018","article-title":"Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type \u03b1-synuclein.","volume":"117","author":"Subramaniam","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbr.2017.05.040","article-title":"Testing cognitive functions in rodent disease models: Present pitfalls and future perspectives.","volume":"352","author":"Tanila","year":"2018","journal-title":"Behav. Brain Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2010.03.004","article-title":"Behavioral phenotyping of mouse models of Parkinson\u2019s disease.","volume":"211","author":"Taylor","year":"2010","journal-title":"Behav. Brain Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/archpsyc.59.10.946","article-title":"Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease.","volume":"59","author":"Tiraboschi","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"B121","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.parkreldis.2004.10.014","article-title":"Dementia with Lewy bodies and Parkinson\u2019s disease with dementia: Are they different?","volume":"11","author":"Tsuboi","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"key":"B122","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1755-5949.2010.00166.x","article-title":"Effects of cholinesterase inhibitors in Parkinson\u2019s disease dementia: A review of clinical data.","volume":"17","author":"van Laar","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/jnc.13627","article-title":"How can rAAV-\u03b1-synuclein and the fibril \u03b1-synuclein models advance our understanding of Parkinson\u2019s disease?","volume":"139","author":"Volpicelli-Daley","year":"2016","journal-title":"J. Neurochem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: Systematic review with meta-analysis and trial sequential analysis.","volume":"86","author":"Wang","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B125","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/01688639508405165","article-title":"Meta-analytic comparison of the components of visual cognition in Parkinson\u2019s disease.","volume":"17","author":"Waterfall","year":"1995","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1750-3639.2010.00373.x","article-title":"Profile of cognitive impairment in Parkinson\u2019s disease.","volume":"20","author":"Watson","year":"2010","journal-title":"Brain Pathol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000087043","article-title":"Dimensions of executive function in Parkinson\u2019s disease.","volume":"20","author":"Weintraub","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B128","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/ageing\/afi190","article-title":"Systematic review of prevalence and incidence studies of dementia with Lewy bodies.","volume":"34","author":"Zaccai","year":"2005","journal-title":"Age Ageing"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-02065-z","article-title":"Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson\u2019s disease model.","volume":"18","author":"Zhang","year":"2021","journal-title":"J. Neuroinflammn."},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136273","article-title":"Cortical alpha-synuclein preformed fibrils do not affect interval timing in mice.","volume":"765","author":"Zhang","year":"2021","journal-title":"Neurosci. Lett."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42286-8","article-title":"Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice.","volume":"9","author":"Zhao","year":"2019","journal-title":"Sci. Rep."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1809","article-title":"APOE4 exacerbates \u03b1-synuclein pathology and related toxicity independent of amyloid.","volume":"12","author":"Zhao","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"9863","DOI":"10.1074\/jbc.M710232200","article-title":"Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: A progressive neurodegenerative model of diffuse Lewy body disease.","volume":"283","author":"Zhou","year":"2008","journal-title":"J. Biol. Chem."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1369733\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:57:16Z","timestamp":1721624236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1369733\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":133,"alternative-id":["10.3389\/fnagi.2024.1369733"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2024.1369733","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1369733"}}